EV-202: EV/Pembro Combo Shows 39% ORR in First-Line PD-L1+ HNSCC | Targeted Oncology

Enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) yielded meaningful clinical activity as first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with a PD-L1…

Continue Reading